Distinguished in Gallbladder Cancer

Dr. Laura W. Goff

Hematology Oncology | Oncology | Hematology
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
 (724.9 mi)
Accepting New Patients
Offers Telehealth
Distinguished in Gallbladder Cancer
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
 (724.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Laura Goff is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Goff and is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Cancer. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization. Dr. Goff is currently accepting new patients.

Her clinical research consists of co-authoring 55 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 2 clinical trials in the study of Gallbladder Cancer.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in TN
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Spanish
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Alliant Health
  •  Oscar

Locations

VANDERBILT HEALTH CLINICIANS, LLC
3601 The Vanderbilt Clinic, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Biological, Drug
Study Drugs: Olaparib, Ramucirumab
Study Phase: Phase 1/Phase 2
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: July 19, 2024
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Varlilumab
Study Phase: Phase 2
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: CPI 613, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Enrollment Status: Terminated
Publish Date: June 05, 2024
Intervention Type: Drug, Other
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: November 01, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Enrollment Status: Terminated
Publish Date: May 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors
A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors
Enrollment Status: Completed
Publish Date: October 09, 2018
Intervention Type: Drug, Other
Study Phase: Phase 1
View 12 Less Clinical Trials

55 Total Publications

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 13, 2024
Similar Doctors
Dana B. Cardin
Advanced in Gallbladder Cancer
Dr. Dana B. Cardin
Hematology Oncology | Oncology | Hematology
Advanced in Gallbladder Cancer
Dr. Dana B. Cardin
Hematology Oncology | Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dana Cardin is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Cardin and is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Cancer. Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, and Colorectal Cancer. Dr. Cardin is currently accepting new patients.

Advanced in Gallbladder Cancer
Dr. Dana Thompson
Oncology
Advanced in Gallbladder Cancer
Dr. Dana Thompson
Oncology

Tennessee Oncology PLLC

1750 Cedar Ln, Suite 200, 
Tullahoma, TN 
 (61.5 mi)
615-333-2481
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dana Thompson is an Oncologist in Tullahoma, Tennessee. Dr. Thompson and is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Cancer. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Colorectal Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Experienced in Gallbladder Cancer
Dr. Olaide I. Ajayi
Hematology Oncology | Hematology | Oncology
Experienced in Gallbladder Cancer
Dr. Olaide I. Ajayi
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

1750 Cedar Ln, Suite 200, 
Tullahoma, TN 
 (61.5 mi)
615-333-2481
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Olaide Ajayi is a Hematologist Oncology specialist and a Hematologist in Tullahoma, Tennessee. Dr. Ajayi and is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Anemia, and Thrombocytopenia. Dr. Ajayi is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile